Summary
The Cigna Group's 2022 10-K filing reveals a robust financial performance, demonstrating resilience and strategic growth. The company reported a 24% increase in shareholders' net income, reaching $6.7 billion, driven by strong operational performance and the gain from the sale of international businesses. Adjusted income from operations saw a 4% increase to $7.3 billion, reflecting growth in both the Evernorth Health Services and Cigna Healthcare segments, supported by improved medical care ratios and cost management. Evernorth Health Services, the company's pharmacy and care solutions platform, experienced a 6% increase in adjusted revenues to $140.3 billion, fueled by strong specialty pharmacy performance and collaborative agreements. Cigna Healthcare, encompassing medical benefits, saw a 1% rise in adjusted revenues to $45 billion, benefiting from disciplined pricing and growth in specific market segments. The company also actively managed its capital, returning approximately $7.6 billion to shareholders through share repurchases and dividends, while maintaining a solid liquidity position. Strategic investments, including a significant commitment to VillageMD, highlight Cigna's focus on future growth and value-based care initiatives.
Financial Highlights
52 data points| Revenue | $180.52B |
| Cost of Revenue | $124.83B |
| Gross Profit | $55.68B |
| SG&A Expenses | $13.17B |
| Operating Income | $8.45B |
| Interest Expense | $1.30B |
| Net Income | $6.70B |
| EPS (Basic) | $21.66 |
| EPS (Diluted) | $21.41 |
| Shares Outstanding (Diluted) | 313.06M |
Key Highlights
- 1Shareholders' net income increased by 24% to $6.7 billion, driven by operational improvements and a gain from divested businesses.
- 2Adjusted income from operations grew 4% to $7.3 billion, demonstrating sustained profitability across key segments.
- 3Evernorth Health Services reported a 6% increase in adjusted revenues to $140.3 billion, driven by specialty pharmacy and cost affordability improvements.
- 4Cigna Healthcare's adjusted revenues grew 1% to $45 billion, supported by disciplined pricing and growth in U.S. Commercial and International Health segments.
- 5The company returned approximately $7.6 billion to shareholders via share repurchases and $1.4 billion through dividends in 2022.
- 6Capital expenditures focused on technology investments, with $1.3 billion allocated in 2022, expected to rise to $1.4 billion in 2023.
- 7Strategic investment in VillageMD up to $2.7 billion demonstrates a commitment to primary care and value-based care models.